help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chihara, K.
Right arrow Articles by Fujita, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chihara, K.
Right arrow Articles by Fujita, T.

Journal of Clinical Endocrinology & Metabolism, Vol 58, 81-86, Copyright © 1984 by Endocrine Society

ARTICLES

Stimulation of growth hormone by vasoactive intestinal polypeptide in acromegaly

K Chihara, H Kaji, N Minamitani, H Kodama, T Kita, B Goto, T Chiba, DH Coy and T Fujita

Vasoactive intestinal polypeptide (VIP) was administered as an iv bolus of 1 micrograms/kg BW to 8 acromegalic patients and in doses of 0.5 and 1 microgram/kg BW to 15 normal volunteers. Both systolic and diastolic blood pressures decreased, and pulse rate increased transiently after VIP injection. VIP stimulated PRL release from the anterior pituitary in normal subjects. Plasma PRL responses to VIP in women were dose dependent and larger than those in men. On the other hand, plasma GH levels rose markedly after VIP injection in all 6 patients with untreated acromegaly. In 2 patients studied after transsphenoidal microadenomectomy, there was no plasma GH response to VIP. In 2 other patients with inactive acromegaly as well as in normal subjects, VIP failed to affect plasma GH levels. In all 6 patients with active acromegaly, LRH (1-2 micrograms/kg BW, iv) did not increase plasma GH levels, but TRH (5-10 micrograms/kg BW, iv) caused significant increases in plasma GH, the magnitude of which was not similar to that of increases seen after VIP injection. Paradoxical GH responses to TRH were not observed in patients in the inactive phase after transsphenoidal surgery. These findings suggest that VIP stimulates GH release in vivo in acromegalic patients. A VIP test as well as a TRH test offer promise as simple and reliable techniques to evaluate the activity of acromegaly, particularly after transsphenoidal surgery.


This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
B. BARANOWSKA, M. RADZIKOWSKA, E. WASILEWSKA-DZIUBINSKA, K. ROGUSKI, and M. BOROWIEC
The Role of VIP and Somatostatin in the Control of GH and Prolactin Release in Anorexia Nervosa and in Obesity
Ann. N.Y. Acad. Sci., December 1, 2000; 921(1): 443 - 455.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Lanzi, M. Losa, G. Mignogna, A. Caumo, and A. E. Pontiroli
The Control on Growth Hormone Release by Free Fatty Acids Is Maintained in Acromegaly
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1234 - 1238.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. G. Maheshwari, S. S. Pezzoli, A. Rahim, S. M. Shalet, M. O. Thorner, and G. Baumann
Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance
Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E943 - E951.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society